Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Terminated 3Completed 2

Sponsor Class

OTHER 18NIH 9INDUSTRY 5NETWORK 3

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 166Lymphoid 21Other hematologic neoplasm 10Thoracic 5Tumor-Agnostic 3Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Sarcoma 1Myeloid 1Gynecologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Pathologic Complete Response 1Neoplasm Metastasis 1NSCLC 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Bortezomib × Thoracic × Clear all
NCT00117351 2011-02-17

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Millennium Pharmaceuticals, Inc.

Phase 2 Terminated
Thoracic

Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00283634 2011-02-17

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Terminated
Thoracic

NSCLC

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00051974 2008-02-11

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
155 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00064636 2005-06-24

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
46 enrolled
Other solid neoplasmThoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡